Franz B. Humer - 05 Dec 2024 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Reporting relationship: Director
Issuer ticker: ALLO
Reported as of: 05 Dec 2024
Net transaction value: -$19,917
SEC form: 4
Accepted by SEC: 09 Dec 2024, 16:05:52 UTC
Prior SEC filing: 07 Jun 2024
Next SEC filing: 23 Jun 2025
Source filing: View source filing
Reporting owner signature: Earl Douglas, Attorney-in-fact

Key filing fact

Franz B. Humer filed Form 4 for Allogene Therapeutics, Inc. (ALLO) on 09 Dec 2024.

Key facts

This page summarizes Franz B. Humer's Form 4 filing for Allogene Therapeutics, Inc. (ALLO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 09 Dec 2024, 16:05.

Change

Previous filing in this sequence was filed on 07 Jun 2024.
Current net transaction value: -$19,917.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ALLO transaction

Common Stock

Sale

Transaction value: $19,917
Shares: -9,221
Change %: -2.9%
Price: $2.16
Shares after: 307,507
Date: 05 Dec 2024
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices raging from $2.145 to $2.185, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC remarks

Exhibits: Power or Attorney